Glioblastoma Immune Landscape and the Potential of New Immunotherapies - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Frontiers in Immunology Année : 2020

Glioblastoma Immune Landscape and the Potential of New Immunotherapies

Résumé

Glioblastoma (GBM) are the most common tumors of the central nervous system and among the deadliest cancers in adults. GBM overall survival has not improved over the last decade despite optimization of therapeutic standard-of-care. While immune checkpoint inhibitors (ICI) have revolutionized cancer care, they unfortunately have little therapeutic success in GBM. Here, we elaborate on normal brain and GBM-associated immune landscapes. We describe the role of microglia and tumor-associated macrophages (TAMs) in immune suppression and highlight the impact of energy metabolism in immune evasion. We also describe the challenges and opportunities of immunotherapies in GBM and discuss new avenues based on harnessing the anti-tumor activity of myeloid cells, vaccines, chimeric antigen receptors (CAR)-T and -NK cells, oncolytic viruses, nanocarriers, and combination therapies.

Dates et versions

hal-03453980 , version 1 (29-11-2021)

Identifiants

Citer

Thomas Daubon, Audrey Hemadou, Irati Romero-Garmendia, Maya Saleh. Glioblastoma Immune Landscape and the Potential of New Immunotherapies. Frontiers in Immunology, 2020, 11 (5), pp.941. ⟨10.3389/fimmu.2020.585616⟩. ⟨hal-03453980⟩

Collections

INSERM CNRS
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More